LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Digital Pathology Solution Resolves the Tissue Floater Conundrum

By LabMedica International staff writers
Posted on 30 Jul 2020
Print article
Image: The Aperio AT2 is the ideal digital pathology slide scanner for high-throughput clinical laboratories, delivering precise eSlides with low rescan rate (Photo courtesy of Leica Biosystems).
Image: The Aperio AT2 is the ideal digital pathology slide scanner for high-throughput clinical laboratories, delivering precise eSlides with low rescan rate (Photo courtesy of Leica Biosystems).
In routine clinical practice, pathologists may encounter extraneous pieces of tissue on glass slides that could be because of contamination from other specimens. These are typically called tissue floaters. The dilemma pathologists often face is whether such a tissue floater truly belongs to the case in question, or if instead it represents a true contaminant from another patient’s sample in which case it should be ignored.

There are currently several measures a pathologist can employ to troubleshoot the tissue floater problem. Akin to forensic analysis, some laboratories have implemented molecular techniques (e.g., DNA fingerprinting for tissue identity testing) to try resolve this problem by dissecting, testing, and then comparing the molecular results of the tissue floater to the adjacent patient sample on the glass slide.

Clinical Pathologists at the University of Michigan (Ann Arbor, MI, USA) and their colleagues demonstrated the feasibility of using an image search tool to resolve the tissue floater conundrum. A glass slide was produced containing two separate hematoxylin and eosin (H&E)-stained tissue floaters. This fabricated slide was digitized along with the two slides containing the original tumors used to create these floaters. These slides were then embedded into a dataset of 2,325 whole slide images comprising a wide variety of H&E stained diagnostic entities. Digital slides were broken up into patches and the patch features converted into barcodes for indexing and easy retrieval. A deep learning-based image search tool was employed to extract features from patches via barcodes, hence enabling image matching to each tissue floater.

All three slides were then entirely digitized at ×40 magnification using an Aperio AT2 whole slide scanner (Leica Biosystems, Richmond, IL, USA). The quality of these digital slides was checked to avoid inclusion of unique identifiers All the slides were then entirely digitized at ×40 magnification using an Aperio AT2 scanner. The quality of these digital slides was checked to avoid inclusion of unique identifiers. These whole slide images (WSIs) included cases from a wide variety of anatomic sites (e.g., colon, brain, thyroid, prostate, breast, kidney, salivary gland, skin, soft tissue, etc.) exhibiting varied diagnostic pathologic entities (i.e., reactive, inflammatory, benign neoplasms, and malignancies).

The scientists reported that there was a very high likelihood of finding a correct tumor match for the queried tissue floater when searching the digital database. Search results repeatedly yielded a correct match within the top three retrieved images. The retrieval accuracy improved when greater proportions of the floater were selected. The time to run a search was completed within several milliseconds. The image search results for matching tissue floaters when using the UPMC 300 WSI pilot dataset showed that the median rank best result for both the bladder and colon tumor was 1 (95% CI =1) when selecting 5% up to 100% of the floater region.

The authors concluded that using an image search tool offers pathologists an additional method to rapidly resolve the tissue floater conundrum, especially for those laboratories that have transitioned to going fully digital for primary diagnosis. The study was published on July 15, 2020 in the journal Archives of Pathology & Laboratory Medicine.



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.